Gastro-esophageal Reflux Disease (GERD) Completed Phase 3 Trials for Dexlansoprazole (DB05351)

Also known as: Gastroesophageal Reflux Disease / Gastro-esophageal Reflux Disease / GERD / GERD Gastroesophageal Reflux Disease / Gastro-Oesophageal Reflux Disease / Gastrooesophageal reflux disease / GERD (Gastroesophageal Reflux Disease) / Esophageal Reflux / GERD - Gastro-Esophageal Reflux Disease / Gastroesophageal Reflux Disease (GERD) / Gastro-esophageal Reflux Diseases / Oesophageal reflux / Esophagitis / Gastrooesophageal reflux / Gastroesophageal reflux / Esophageal reflux NOS

IndicationStatusPhase
DBCOND0077290 (Gastro-esophageal Reflux Disease (GERD))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02873689Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese PatientsTreatment
NCT00251758Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat HeartburnTreatment
NCT00251745Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat HeartburnTreatment
NCT00255190Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat HeartburnTreatment
NCT00321984Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux DiseaseTreatment